Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/3048% above fair value
$0.91−0.08 (-7.64%)
Close on Nov 13, 2026Market cap $231.31MP/E –Yield –
Lineage Cell Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Lineage Cell Therapeutics's enterprise value was $228.78M on Nov 11, 2026, against $363.65M a year earlier. Over the last 5 years it ranged from $49.80M to $409.81M, with a median of $178.59M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $228.78M | -33.3% |
| 2025 | Dec 31, 2025 | $342.92M | +464.1% |
| 2024 | Dec 31, 2024 | $60.79M | -58.9% |
| 2023 | Dec 29, 2023 | $147.95M | +12.9% |
| 2022 | Dec 30, 2022 | $131.02M | -62.2% |
| 2021 | Dec 31, 2021 | $346.52M | +54.1% |
| 2020 | Dec 31, 2020 | $224.90M | +134.3% |
| 2019 | Dec 31, 2019 | $95.98M | +3.4% |
| 2018 | Dec 31, 2018 | $92.84M | -61.8% |
| 2017 | Dec 29, 2017 | $243.06M | -32.0% |
| 2016 | Dec 30, 2016 | $357.58M | +0.7% |
| 2015 | Dec 31, 2015 | $355.17M | +29.0% |
| 2014 | Dec 31, 2014 | $275.33M | +33.7% |
| 2013 | Dec 31, 2013 | $205.95M | +29.7% |
| 2012 | Dec 31, 2012 | $158.81M | -41.5% |
| 2011 | Dec 30, 2011 | $271.47M | – |
See a number that looks wrong?